Cancer Immunotherapy Research Program

项目总结/摘要 癌症免疫学 埃默里大学温希普癌症研究所（Winship）的癌症免疫学（CI）项目进行了 旨在通过利用免疫系统来预防和治疗癌症的研究。增加了CI程序 作为2019年的一项新的科学计划，汇集了越来越多的教师进行基础，临床， 癌症免疫学的转化研究。CI计划的总体目标是进行 转型研究，以减少患者和癌症风险人群的癌症负担。癌 Winship的免疫学研究已经为免疫学的发展做出了开创性的贡献。 癌症的免疫疗法，并帮助定义了指导免疫疗法的基本原则 反应该计划的总体科学目标是：（1）确定细胞和分子机制 抗肿瘤免疫的潜在调节，和（2）发现和测试新的免疫方法来治疗 或预防癌症。在Madhav Dhodapkar的领导下，MBBS（领导者）和Rafi Ahmed博士（合作者） 领导者），CI计划包括25个核心成员，代表11个不同的部门在学校 医学（SOM）。这个高度合作的研究小组共发表了293篇与癌症相关的文章， 在目前的资助期内，科学论文。其中，49例（17%）为内部，127例（43%）为内部。 方案合作，197（67%）涉及与另一个机构的合作，89（30%）是 发表在影响因子> 10的期刊上。截至2021年12月31日，CI成员持有915万美元， 年度计划直接成本，其中640万美元是同行评审的，350万美元（55%）是奖励的 从国家癌症研究所项目成员在几个Winship团队科学项目中发挥领导作用，包括 NCI资助的肺癌SPORE和P01奖项以及白血病和淋巴瘤协会专业中心 多发性骨髓瘤研究奖（SCOR），均为报告期内新颁发的奖项。影响力CI 科学贡献包括i）开发阿巴西普以预防急性移植物抗宿主病， 导致FDA在2021年批准，ii）肿瘤微环境中抗原特异性B和T细胞的定义， 具有实践改变免疫学意义的头颈癌，iii）抗原的鉴定- 肿瘤内的呈递细胞小生境，这可能是免疫逃逸的关键机制，以及iv）肿瘤内呈递细胞小生境的定义。 在PD-1免疫治疗后提供增殖爆发的CD 8 T细胞。CI项目负责人开发 方案内容，会议和务虚会，并培养一个丰富多样的研究环境， 加强对下一代癌症研究人员的培训，并促进未成年人的职业发展， 代表学者。CI与Winship Community Outreach and Engagement（COE）密切互动， 与社区利益相关者进行双向沟通。建立在 Winship为创新和团队科学提供支持资源和基础设施，包括超过85万美元的试点项目 CI将为癌症免疫学和免疫治疗领域做出重大贡献。

PROJECT SUMMARY/ABSTRACT CANCER IMMUNOLOGY PROGRAM The Cancer Immunology (CI) Program of Winship Cancer Institute of Emory University (Winship) conducts research that seeks to prevent and treat cancer by harnessing the immune system. The CI program was added as a new scientific program in 2019 to bring together the growing number of faculty conducting basic, clinical, and translational research in cancer immunology at Winship. The overall goal of the CI program is to conduct transformational research to reduce the cancer burden among patients and populations at risk for cancer. Cancer immunology research at Winship has already made seminal contributions to the development of immunotherapies for cancer and has helped to define fundamental principles that guide immunotherapy response. The overall scientific goals of the program are: (1) to identify the cellular and molecular mechanisms underlying regulation of anti-tumor immunity, and (2) to discover and test new immunologic approaches to treat or prevent cancer. Under the leadership of Madhav Dhodapkar, MBBS (leader), and Rafi Ahmed, PhD (co- leader), the CI Program includes 25 core members representing 11 different departments within the School of Medicine (SOM). This highly collaborative group of researchers has published a total of 293 cancer-relevant scientific articles during the current funding period. Of these, 49 (17%) were intra- and 127 (43%) were inter- programmatic collaborations, 197 (67%) involved a collaboration with another institution and 89 (30%) were published in journals with an impact factor > 10. As of December 31, 2021, CI members held $9.15 million in annual program direct costs, of which $6.4 million was peer-reviewed and $3.5 million (55%) was awarded from the NCI. Program members play leadership roles in several Winship team science programs including NCI-funded lung cancer SPORE and P01 awards and a Leukemia and Lymphoma Society Specialized Center of Research (SCOR) award in multiple myeloma, all newly awarded during the reporting period. Impactful CI scientific contributions include i) development of abatacept to prevent acute graft versus host disease, ultimately leading to FDA approval in 2021, ii) definition of antigen-specific B and T cells in tumor microenvironment of head/neck cancer with practice-changing immunotherapeutic implications, iii) identification of antigen- presenting-cell niches within tumors that may be key mechanism of immune escape, and iv) definition of the CD8 T cells that provide the proliferative burst after PD-1 immunotherapy. CI program leaders develop programmatic content, meetings, and retreats, and foster a rich and diverse research environment which enhances training for the next generation of cancer researchers and promotes career development of under- represented scholars. CI interacts closely with Winship Community Outreach and Engagement (COE) to address catchment area priorities and engage in bi-directional communication with community stakeholders. Built on Winship's enabling resources and infrastructure for innovation and team-science, including >$850,000 of pilot funding, CI is poised to make major contributions to the field of cancer immunology and immunotherapy.